ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Radius Announces Update on Tymlos (abaloparatide) Label
December 29, 2021Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that the U.S. Food and Drug Administration (FDA) has approved updates to the Tymlos label, including the removal of the boxed warning regarding the risk of osteosarcoma. -
Radius Health Announces Commercial Agreement with Paladin Labs for Abaloparatide in Canada
January 13, 2021Radius Health has entered into definitive agreements with Endo Ventures Limited, a subsidiary of Endo International, to register, commercialize, and distribute abaloparatide on an exclusive basis in Canada.
Pharma Sources Insight January 2025
